Bluestar Genomics Announces Plans to Present at the 40th Annual J.P. Morgan Healthcare Conference January 12 at 4:30 p.m. Eastern Time

Management to share updates on company’s non-invasive cancer detection programs

SAN DIEGO--(BUSINESS WIRE)--Bluestar Genomics, Inc., an early cancer detection company leading the development and commercialization of next-generation liquid biopsy approaches initially focused on non-invasive detection of high-mortality cancers, today announced that management will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 12 at 4:30 p.m. ET.

This will be Bluestar Genomics’ first J.P. Morgan Healthcare Conference presentation, which will be followed by a 10-minute question-and-answer session and one-on-one meetings with investors. Samuel Levy, Ph.D., acting chief executive officer and chief scientific officer at Bluestar Genomics, will provide an update on the company’s development and commercialization efforts for its non-invasive epigenomic tests.

“We are pleased to be invited to present at the J.P. Morgan Healthcare Conference to share our technology story and commercialization roadmap with the investment community,” said Samuel Levy, Ph.D., acting chief executive officer and chief scientific officer at Bluestar Genomics. “As we continue to focus on the deadliest types of cancer that currently lack early detection protocols, 2022 proves to be a transformative year for our company and industry as we seek to improve non-invasive cancer detection.”

About Bluestar Genomics

Bluestar Genomics is an early cancer detection company focused on the development and commercialization of non-invasive epigenomic tests to detect cancer through a standard blood draw, earlier than existing methods and when the disease is still treatable. The company uses its one-of-a-kind epigenomic platform that combines best-in-class bioinformatics and genomic technologies to analyze individuals’ changing biology that is yet to produce symptoms. Leveraging its novel liquid biopsy technology, Bluestar Genomics is initially focused on high-mortality cancers with the greatest need for early detection, starting with pancreatic and women’s cancers. With locations in San Diego and the San Francisco Bay Area, Bluestar Genomics collaborates with top research institutions and is supported by multiple global healthcare and technology investors and pharmaceutical collaborations. For more information, visit https://www.bluestargenomics.com or follow us on Twitter @BluestarGenomix.